β1整合素（极晚期抗原-4和-5）在骨髓瘤细胞上的表达及多发性骨髓瘤患者的临床相关性

Expression of beta 1 integrins (very late antigens-4 and -5) on myeloma cells and clinical correlates in patients with multiple myeloma.

作者信息

Nishinarita S, Shimada H, Ito T, Namiki H, Kawahira H, Sawada U, Horie T

机构信息

First Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.

出版信息

J Int Med Res. 1998 Jan-Feb;26(1):37-42. doi: 10.1177/030006059802600104.

DOI:10.1177/030006059802600104

PMID:9513075

Abstract

beta 1 Integrins are considered to be essential for the differentiation of bone-marrow B cells through an interaction with fibronectin-expressed bone-marrow stromal cells. The expression of very late antigens-4 (VLA-4) and -5 (VLA-5) by CD38bright bone-marrow cells in patients with multiple myeloma was measured by flow cytometry using specific monoclonal antibodies. The percentage of CD38bright bone-marrow cells appeared to correlated with that of bone-marrow plasma cells as judged by examination of bone-marrow smears (r = 0.911, P < 0.0001). Expression of VLA-4 and VLA-5 by CD38bright cells varied between patients, but the expression of VLA-4 was always equal to or greater than that of VLA-5. The ratio of VLA-4 to VLA-5 expression (VLA-4:VLA-5 ratio) was calculated and compared with the clinical features of the myeloma patients. A high VLA-4:VLA-5 ratio (> 2.0) was associated with the presence of plasmacytomas and urinary Bence-Jones protein was more common in this group. No other correlations between the clinical features of the disease and the expression of beta 1 integrins were found.

摘要

β1整合素被认为通过与表达纤连蛋白的骨髓基质细胞相互作用，对骨髓B细胞的分化至关重要。使用特异性单克隆抗体通过流式细胞术检测多发性骨髓瘤患者CD38bright骨髓细胞上极晚期抗原-4（VLA-4）和-5（VLA-5）的表达。通过骨髓涂片检查判断，CD38bright骨髓细胞的百分比似乎与骨髓浆细胞的百分比相关（r = 0.911，P < 0.0001）。CD38bright细胞上VLA-4和VLA-5的表达在患者之间有所不同，但VLA-4的表达总是等于或大于VLA-5的表达。计算VLA-4与VLA-5表达的比值（VLA-4:VLA-5比值），并与骨髓瘤患者的临床特征进行比较。高VLA-4:VLA-5比值（> 2.0）与浆细胞瘤的存在相关，并且该组中尿本-周蛋白更常见。未发现疾病的临床特征与β1整合素表达之间的其他相关性。